Dalton expands sterile fill/finish capabilities


The Toronto-based pharma services company said investment is part of a US$10m facility and capital expansion

Dalton Pharma Services has announced the addition of an automated sterile liquid filling to its manufacturing capacity. Headquartered in Toronto, Canada, Dalton is a contract research, development and manufacturing organisation (RDMO).

The investment, the company said, is part of a ten-million-dollar facility and capital expansion.

“The flexibility and aseptic assurance that this new fill-line provides will enable Dalton to extend services beyond the current clinical stage and accelerate the development of clients` sterile drug products to reach the market, faster,” said Peter Pekos, Dalton CEO and President.

The new fill line, which is a fully automated sterile liquid filling system, allows larger batch sizes (~40 BPM), a broader range of filling volumes and container closure systems. It also provides nitrogen purging and individual bottle serialisation.

Sign up for your free email newsletter

The equipment will become operational in Q1 of 2019.